Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) EBITDA (2016 - 2025)

Historic EBITDA for Neuroone Medical Technologies (NMTC) over the last 14 years, with Q4 2025 value amounting to -$1.7 million.

  • Neuroone Medical Technologies' EBITDA fell 19977.21% to -$1.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.6 million, marking a year-over-year decrease of 1266.61%. This contributed to the annual value of -$4.2 million for FY2025, which is 6444.52% up from last year.
  • Latest data reveals that Neuroone Medical Technologies reported EBITDA of -$1.7 million as of Q4 2025, which was down 19977.21% from -$1.4 million recorded in Q3 2025.
  • In the past 5 years, Neuroone Medical Technologies' EBITDA ranged from a high of $1.7 million in Q4 2024 and a low of -$3.5 million during Q2 2023
  • Over the past 5 years, Neuroone Medical Technologies' median EBITDA value was -$2.8 million (recorded in 2022), while the average stood at -$2.4 million.
  • Per our database at Business Quant, Neuroone Medical Technologies' EBITDA skyrocketed by 15047.1% in 2024 and then crashed by 19977.21% in 2025.
  • Neuroone Medical Technologies' EBITDA (Quarter) stood at -$2.8 million in 2021, then skyrocketed by 36.48% to -$1.8 million in 2022, then plummeted by 90.01% to -$3.4 million in 2023, then surged by 150.47% to $1.7 million in 2024, then crashed by 199.77% to -$1.7 million in 2025.
  • Its EBITDA was -$1.7 million in Q4 2025, compared to -$1.4 million in Q3 2025 and -$1.9 million in Q2 2025.